Enabling AI in the pharmaceutical sector

Reading Time: 3 minutes

 

Artificial Intelligence (AI) is a very topical subject although the art of using computers to mimic human cognition has been with us for a number of years. Earlier CI Consulta’s Insights Institute in partnership with GRTU, Microsoft and the University of Malta, organised a briefing session on the use of AI in the pharmaceutical sector. 

 Kyle Anastasi, Account Technology Strategist, at Microsoft Malta showed various case studies on how AI can be used to improve the experience of the patient as well as gain additional intelligence from already available data at health centres that help in the delivery of a better cure and service. 

He highlighted how through available applications (some free of charge) based on artificial intelligence, persons with critical lifetime impairments such as blindness and Parkinsons can have their quality of life substantially improved through the use of devices which lead them to experience life events that otherwise will not be possible. 

 Project Emma is a wearable device initially created to help a specific person suffering from Parkinson’s, Emma Lawton, to compensate for the intentional tremors in her hands.

Project Emma is named after Emma, who was diagnosed with early-onset Parkinson’s at age 29.  Seeing AI is a free app that narrates the world around you. Designed for the low vision community, this research project harnesses the power of AI to describe people, text and objects

 Prof Alexiei Dingli, Head of Department of AI, University of Malta, showed a number of practical examples on how AI can improve the operations of the pharmaceutical sector, including the operations of local health centers and pharmacies. 

Through real-life case studies he showed how AI can improve various aspects of a pharmacy including the scheduling of client appointments, the availability of 24/7 assistance, the recording of client data and the logging of administrative details including supplier invoices. 

 The session was very well attended by representatives from the local pharmaceutical sector, who actively participated in the discussion on how technology can be integrated in the daily operations and the delivery of a better service. 

The overriding message was that the integration of AI can be phased and adopted through piece-meal approach, starting from areas of a commercial operation which is currently highly reliant on human intervention and where substantial amounts of data is recorded. 

The introduction of AI follows a thorough cost-benefit analysis although the vast developments in the area have greatly reduced the initial investment needed to introduce smart technologies in any commercial activity. 

 Abigail Mamo, CEO, GRTU spoke about the importance of technology in increasing the competitiveness of small enterprises and reiterated GRTU’s commitment to increase awareness on AI and facilitate its adoption among its sectors. 

She encouraged GRTU members to identify sections of their business where the use of technology can improve the delivery of a service and potentially save financial and other resources. 

 Through its network of experts CI Consulta is uniquely positioned to advise on the use of AI in the pharmaceutical and other sectors. 

Following a situation analysis, recommendations can be made on how AI can tangibly improve the delivery of any service. For further information contact ciconsulta@corporateidgroup.com

%d bloggers like this: